Castellum (NYSEAMERICAN:CTM – Get Free Report) was upgraded by equities researchers at Maxim Group to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.
Castellum Stock Performance
Shares of Castellum stock opened at $1.01 on Thursday. The firm has a market cap of $70.64 million, a P/E ratio of -5.94 and a beta of -12.75. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.11 and a quick ratio of 1.11. The firm has a 50 day simple moving average of $1.03 and a 200 day simple moving average of $0.67. Castellum has a fifty-two week low of $0.12 and a fifty-two week high of $2.83.
Insiders Place Their Bets
In other Castellum news, Director Mark C. Fuller sold 275,000 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $1.49, for a total value of $409,750.00. Following the completion of the transaction, the director now directly owns 7,338,659 shares of the company’s stock, valued at approximately $10,934,601.91. The trade was a 3.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 45.55% of the company’s stock.
Institutional Inflows and Outflows
About Castellum
Castellum, Inc provides services in the areas of cybersecurity, information technology, electronic and information warfare, and information operations. Its services include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and model based systems engineering services.
Featured Stories
- Five stocks we like better than Castellum
- 5 Top Rated Dividend Stocks to Consider
- Short Sellers Gave Up on These 3 Names Recently
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Boring Stocks Outperforming the Market This Year
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
Receive News & Ratings for Castellum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castellum and related companies with MarketBeat.com's FREE daily email newsletter.